Sonoma Pharmaceuticals (SNOA) Long-Term Deferred Tax (2022 - 2026)

Sonoma Pharmaceuticals' Long-Term Deferred Tax history runs 5 years deep, the most recent figure standing at $884000.0 for Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 50.08% year-over-year to $884000.0 in Q1 2026; TTM through Mar 2026 was $884000.0, a 50.08% increase from a year earlier, with the FY2026 full-year figure at $884000.0, up 50.08% from the prior year.
• Long-Term Deferred Tax grew to $884000.0 in Q1 2026 per SNOA's latest filing, from $458000.0 in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $1.1 million in Q1 2024 and bottomed at $458000.0 in Q4 2025.
• The 5-year median for Long-Term Deferred Tax is $859000.0 (2022), against an average of $820941.2.
• Across the five-year window, Long-Term Deferred Tax plunged 48.56% in 2025 and soared 50.08% in 2026, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $1.1 million in 2022, then dropped by 15.34% to $922000.0 in 2023, then fell by 17.57% to $760000.0 in 2024, then plunged by 39.74% to $458000.0 in 2025, then surged by 93.01% to $884000.0 in 2026.
• Per Business Quant, the three latest SNOA Long-Term Deferred Tax figures stand at $884000.0 (Q1 2026), $458000.0 (Q4 2025), and $508000.0 (Q3 2025).